Public health response to an outbreak of meningococcal B disease in a secondary school in Far North Queensland
DOI:
https://doi.org/10.33321/cdi.2023.47.50Keywords:
disease outbreak, meningococcal B, Neisseria meningitidis, MenB-4C vaccineAbstract
This article describes the public health response to an outbreak of meningococcal B disease, linked to a secondary school in Far North Queensland. Tropical Public Health Services in Cairns were notified of three cases of meningococcal disease in the same week in May 2022. The cases occurred in individuals who all attended, or worked in, the same secondary school. All cases were serogroup B and shared the same molecular genotype. The public health response included prompt provision of information, distribution of clearance antibiotics and two doses of MenB-4C vaccine to the entire staff and student population. Antibiotic coverage and vaccination coverage were achieved in 99% and 85% of the student population respectively. Following the intervention, no further cases were detected in the region during the subsequent nine months.
Downloads
References
Australian Government Department of Health and Aged Care. Invasive meningococcal disease – CDNA National guidelines for Public Health Units. [Webpage.] Canberra: Australian Government Department of Health and Aged Care, Communicable Diseases Network Australia; July 2017. Available from: https://www.health.gov.au/resources/publications/invasive-meningococcal-disease-cdna-national-guidelines-for-public-health-units?language=en.
Rouphael NG, Stephens DS. Neisseria meningitidis: biology, microbiology and epidemiology. Methods Mol Biol. 2012;799:1–20. doi: https://doi.org/10.1007/978-1-61779-346-2_1.
Australian Technical Advisory Group on Immunisation (ATAGI). Australian Immunisation Handbook. Canberra: Australian Government Department of Health and Aged Care, ATAGI; 2022. [Accessed in November 2022.] Available from: https://immunisationhandbook.health.gov.au/.
Poland GA. Prevention of meningococcal disease: current use of polysaccharide and conjugate vaccines. Clin Infect Dis. 2010;50(Suppl 2):S45–53. doi: https://doi.org/10.1086/648964.
Queensland Government. Immunisation Schedule Queensland – Children. July 2020. Brisbane: Queensland Government; July 2020. [Accessed in July 2022.] Available from: https://www.health.qld.gov.au/__data/assets/pdf_file/0032/989114/qld-immunisation-schedule-children.pdf.
van Kessel F, van den Ende C, Oordt-Speets AM, Kyaw MH. Outbreaks of meningococcal meningitis in non-African countries over the last 50 years: a systematic review. J Glob Health. 2019;9(1):010411. doi: https://doi.org/10.7189/jogh.09.010411.
Davison RP, Lovegrove DR, Selvey LA, Smith HV. Using the national guidelines to manage a meningococcal group C outbreak in a Brisbane boarding school – some discretionary judgements are needed. Commun Dis Intell Q Rep. 2003;27(4);520–3.
Davison KL, Andrews N, White JM, Ramsay ME, Crowcroft NS, Rushdy AA et al. Clusters of meningococcal disease in school and preschool settings in England and Wales: what is the risk? Arch Dis Child. 2004;89(3);256–60. doi:https://doi.org/10.1136/adc.2003.031369.
De Wals P, Hertoghe L, Borlée-Grimée I, De Maeyer-Cleempoel S, Reginster-Haneuse G, Dachy A et al. Meningococcal disease in Belgium. Secondary attack rate among household, day-care nursery and pre-elementary school contacts. J Infect. 1981;3(1 Suppl):53–61. doi: https://doi.org/10.1016/s0163-4453(81)80009-6.
McNamara LA, MacNeil JR, Cohn AC, Stephens DS. Mass chemoprophylaxis for control of outbreaks of meningococcal disease. Lancet Infect Dis. 2018:18(9);e272–81. doi: https://doi.org/10.1016/S1473-3099(18)30124-5.
New Zealand Medicines and Medical Devices Safety Authority (Medsafe). New Zealand data sheet: Bexsero. Wellington: Medsafe; 22 November 2021. {Accessed on 25 November 2022.] Available from: https://www.medsafe.govt.nz/profs/datasheet/b/bexseroinj.pdf.
Medini D, Stella M, Wassil J. MATS: Global coverage estimates for 4CMenB, a novel multicomponent meningococcal B vaccine. Vaccine. 2015;33(23):2629–36. doi: https://doi.org/10.1016/j.vaccine.2015.04.015.
De Wals P, Deceuninck G, Lefebvre B, Tsang R, Law D, De Serres G et al. Impact of an immunization campaign to control an increased incidence of serogroup B meningococcal disease in one region of Quebec, Canada. Clin Infect Dis. 2017;64(9):1263–7. doi: https://doi.org/10.1093/cid/cix154.
South Australian Meningococcal B Expert Working Group. A Meningococcal B Program for South Australia. Public Report 3 July 2018. Adelaide: South Australian Government, Department of Health and Wellbeing, South Australian Meningococcal B Expert Working Group; 3 July 2018. [Accessed on 17 March 2023.] Available from: https://www.sahealth.sa.gov.au/wps/wcm/connect/b82a9fb7-061a-48b9-be37-54e88a1907d1/2018-06+Optimal+Men+B+Program+for+SA+Public+Report+%282%29.pdf.
Tozer SJ, Smith HV, Whiley DM, Borrow R, Boccadifuoco G, Medini D et al. High coverage of diverse invasive meningococcal serogroup B strains by the 4-component vaccine 4CMenB in Australia, 2007-2011: concordant predictions between MATS and genetic MATS. Hum Vaccin Immunother. 2021;17(9):3230–8. doi: https://doi.org/10.1080/21645515.2021.1904758.
Jardine A, Truman G, Sheppeard V, Gibbons D, Thomas J, Weston K. A community outbreak of meningococcal serogroup B disease in western Sydney: the challenges of identification and significance. Commun Dis Intell Q Rep. 2009;33(2):221–4.
Miles TA, Lewis PR, Cook L, Bruderlin KI. An outbreak of meningococcal disease in a secondary school – implications for public health practice. Commun Dis Intell Q Rep. 2004;28(3):345–7.
Gabutti G. Meningococcus B: Control of two outbreaks by vaccination. J Prev Med Hyg. 2014;55(2):35–41.
Public Health England. Guidance for public health management of meningococcal disease in the UK. Updated August 2019. London: United Kingdom Government, Public Health England; 6 August 2019. [Accessed on 23 November 2022.] Available from: https://assets.publishing.service.gov.uk/government/uploads/system/uploads/attachment_data/file/829326/PHE_meningo_disease_guideline.pdf.
Wang B, Afzali HHA, Marshall H. The inpatient costs and hospital service use associated with invasive meningococcal disease in South Australian children. Vaccine. 2014;32(37):4791–8 . doi: https://doi.org/10.1016/j.vaccine.2014.05.069.
Anonychuk A, Woo G, Vyse A, Demarteau N, Tricco AC. The cost and public health burden of invasive meningococcal disease outbreak: a systematic review. Pharmacoeconomics. 2013;31(7):563–76. doi: https://doi.org/10.1007/s40273-013-0057-2.
Gustafsson N, Stallknecht SE, Skovdal M, Poulsen PB, Østergaard L. Societal costs due to meningococcal disease: a national registry-based study. ClinicoEcon Outcomes Res. 2018;10:563–72. doi: https://doi.org/10.2147/CEOR.S175835.
Published
How to Cite
Issue
Section
License
Copyright (c) 2023 Communicable Diseases Intelligence
This work is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License.
